Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL577658 | 0.79 | KDM1A (0.39) | KDM1A | |
| SCHEMBL29608131 | 0.78 | GRIN2D (0.38) | KDM1A | |
| SCHEMBL775690 | 0.75 | KDM1A (0.35) | KDM1A | |
| SCHEMBL3248949 | 0.75 | KDM1A (0.35) | KDM1A | |
| SCHEMBL6561593 | 0.73 | KDM1A (0.34) | KDM1A | |
| SCHEMBL21878050 | 0.72 | — | — | |
| SCHEMBL5845510 | 0.72 | TLR4 (0.35) | KDM1AALDH1A1KMT2A | |
| SCHEMBL23167366 | 0.71 | TERT (0.32) | TP53RECQLBRD4ALDH1A1KMT2A | |
| SCHEMBL5844300 | 0.70 | TLR4 (0.42) | KDM1AALDH1A1TSHRKMT2A | |
| SCHEMBL5846236 | 0.69 | TLR4 (0.41) | KDM1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809594-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2007081895-A2 | PREPARATION OF SUBSTITUTED 2-HYDROXYGIBBA-1(10A), 2, 4, 4B-TETRAEN-6-ONES | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| US-7157604-B2 | Selective estrogen receptor modulators | MERCK & CO., INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7087599-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2006-08-08 | — | — | US | disclosed |
| WO-2006050402-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| EP-1418900-A4 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1257264-A4 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2005-08-10 | — | — | EP | disclosed |
| EP-1339683-A4 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20050137192-A1 | Estrogen receptor modulators | PARKER DANN R JR (US) | 2005-06-23 | — | — | US | disclosed |
| EP-1418900-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-05-19 | — | — | EP | disclosed |
| EP-1339683-A2 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003015761-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1257264-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2002-11-20 | — | — | EP | disclosed |
| WO-2002041835-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2002-05-30 | — | — | WO | disclosed |
| WO-2001082923-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137192-A1 | Estrogen receptor modulators | GPER1, ESR2, ESRRA | KDM1A 371/4885TP53 922/4885RECQL 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.